- Home
- RARE vs ITGR Comparison
RARE vs ITGR Comparison
Compare RARE & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- ITGR
- Stock Information
- Founded
- RARE 2010
- ITGR 1970
- Country
- RARE United States
- ITGR United States
- Employees
- RARE N/A
- ITGR N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- ITGR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RARE Health Care
- ITGR Health Care
- Exchange
- RARE Nasdaq
- ITGR Nasdaq
- Market Cap
- RARE 3.5B
- ITGR 4.2B
- IPO Year
- RARE 2014
- ITGR 2000
- Fundamental
- Price
- RARE $36.68
- ITGR $123.17
- Analyst Decision
- RARE Strong Buy
- ITGR Strong Buy
- Analyst Count
- RARE 15
- ITGR 10
- Target Price
- RARE $90.53
- ITGR $145.90
- AVG Volume (30 Days)
- RARE 1.1M
- ITGR 434.3K
- Earning Date
- RARE 07-31-2025
- ITGR 07-24-2025
- Dividend Yield
- RARE N/A
- ITGR N/A
- EPS Growth
- RARE N/A
- ITGR N/A
- EPS
- RARE N/A
- ITGR 2.18
- Revenue
- RARE $590,689,000.00
- ITGR $1,746,192,000.00
- Revenue This Year
- RARE $18.94
- ITGR $11.03
- Revenue Next Year
- RARE $28.93
- ITGR $7.29
- P/E Ratio
- RARE N/A
- ITGR $56.26
- Revenue Growth
- RARE 33.46
- ITGR 10.19
- 52 Week Low
- RARE $29.59
- ITGR $104.93
- 52 Week High
- RARE $60.37
- ITGR $146.36
- Technical
- Relative Strength Index (RSI)
- RARE 51.86
- ITGR 57.19
- Support Level
- RARE $36.03
- ITGR $116.15
- Resistance Level
- RARE $37.74
- ITGR $120.00
- Average True Range (ATR)
- RARE 1.46
- ITGR 2.23
- MACD
- RARE -0.01
- ITGR 0.20
- Stochastic Oscillator
- RARE 26.56
- ITGR 75.63
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About ITGR Integer Holdings Corporation
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.